6 results about "Anti convulsants" patented technology

The invention belongs to the technical field of organic synthetic chemistry, and particularly relates to a preparation method and medical application of a visible-light-driven bis (trifluoromethyl) selenide compound. The preparation method of the bis (trifluoromethyl) selenide compound comprises the following steps: by taking olefin, trifluoromethylselenotetramethylammonium and bis (trifluoromethylseleno) diselenide as reaction raw materials, stirring and reacting under the conditions of proper temperature and visible light irradiation in the presence of cuprous salt to obtain the bis (trifluoromethyl) selenide compound. The method has the advantages of mild reaction conditions, simplicity and convenience in operation, good functional group compatibility and the like. In addition, the bis (trifluoromethyl) selenide compound provided by the invention shows good potential in the aspect of anticonvulsion, and has the prospect of being further developed into anticonvulsion drugs.

The present invention relates to the pharmaceutical technology. Keratin CF2, methods for producing the same, pharmaceutical compositions containing the same and the use thereof are disclosed, and the present invention particularly relates to keratin CF2, nucleic acid molecules encoding the keratin CF2, expression vectors containing the nucleic acid molecule, host cells containing the expression vector or in which the nucleic acid molecule is incorporated into the genome, methods for producing the keratin CF2, pharmaceutical compositions containing the keratin CF2, and the use of the keratin CF2, nucleic acid molecules, expression vectors, host cells or pharmaceutical compositions in the manufacture of antipyretics, analgesics, antitussives, expectorants, anticonvulsants, antiepileptics, antihypertensives, anti-inflammatorys or antivirals.

A pharmacological method for treating the expressive language deficit in an autistic human child or adult is provided. A therapeutically effective dose of a succinimide anticonvulsant, e.g., ethosuximide, methsuximide, phensuximide, or a pharmaceutically acceptable salt thereof, is administered to a patient suffering from expressive language deficit, preferably over an extended period, e.g., six months or longer. Language gains are retained even after treatment is discontinued.

The present invention provides compositions and methods of preventing, alleviating, or treating a subject with a toxic agent-induced injury. The present invention also provides compositions and methods of preventing, alleviating, or treating a tissue damage caused by exposure to a toxic agent or restoring at least a portion of normal tissue function. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one potassium channel blocker. In some embodiments, the potassium channel blocker comprises 4-aminopyridine, a derivative thereof, or a combination thereof. In some embodiments, the pharmaceutical composition can be administered with an additional therapeutic agent, such as an anticonvulsant.

The present disclosure relates to 1,4,5-substituted 1,2,3-triazoles useful as modulators of pregnane X receptor (PXR) and in the treatment of disorders associated with PXR dysfunction (e.g., disorders of uncontrolled cellular proliferation, bowel disorders). The invention further relates to uses of the disclosed compounds in decreasing adverse drug reactions such as, for example, adverse reactions associated with administration of an anticancer agent, an antibacterial agent, a non-steroidal anti-inflammatory agent, and an anticonvulsant agent. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

A series of novel amides showing broad pharmaceutical activity. Compounds described herein are effective as anticonvulsants, chemical countermeasures, and analgesics. Such compounds also show, neuroprotective / neuroreparative effects and activity against spinal muscular atrophy. Such pharmaceutically active compounds show utility in the treatment of central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's, ALS, and Huntington's disease) spasticity, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), and / or traumatic brain and / or spinal cord injuries.